1. 2019 BioNTech patent admits: mRNA jabs unsuitable as pharmaceutical product because toxic, unstable

    2019 BioNTech patent admits: mRNA jabs unsuitable as pharmaceutical product because toxic, unstable

    16
    0
    566
    3